Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. J. Pongers-Willemse is active.

Publication


Featured researches published by M. J. Pongers-Willemse.


Leukemia | 1998

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

M. J. Pongers-Willemse; O. J. H. M. Verhagen; G. J. M. Tibbe; A. J. M. Wijkhuijs; V de Haas; E. Roovers; C. E. Van Der Schoot; J J M van Dongen

Analysis of minimal residual disease (MRD) can predict outcome in acute lymphoblastic leukemia (ALL). A large prospective study in childhood ALL has shown that MRD analysis using immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements as PCR targets can identify good and poor prognosis groups of substantial size that might profit from treatment adaptation. This MRD-based risk group assignment was based on the kinetics of tumor reduction. Consequently, the level of MRD has to be defined precisely in follow-up samples. However, current PCR methods do not allow easy and accurate quantification. We have tested ‘real-time’ quantitative PCR (RQ-PCR) using the TaqMan technology and compared its sensitivity with two conventional MRD-PCR methods, ie dot-blot and liquid hybridization of PCR amplified Ig/TCR gene rearrangements using clone-specific radioactive probes. In RQ-PCR the generated specific PCR product is measured at each cycle (‘real-time’) by cleavage of a fluorogenic intrinsic TaqMan probe. The junctional regions of rearranged Ig/TCR genes define the specificity and sensitivity of PCR-based MRD detection in ALL and are generally used to design a patient-specific probe. In the TaqMan technology we have chosen for the same approach with the design of patient-specific TaqMan probes at the position of the junctional regions. We developed primers/probe combinations for RQ-PCR analysis of a total of three IGH, two TCRD, two TCRG and three IGK gene rearrangements in four randomly chosen precursor-B-ALL. In one patient, 12 bone marrow follow-up samples were analyzed for the presence of MRD using an IGK PCR target. The sensitivity of the RQ-PCR technique appeared to be comparable to the dot-blot method, but less sensitive than liquid hybridization. Although it still is a relatively expensive method, RQ-PCR allows sensitive, reproducible and quantitative MRD detection with a high throughput of samples providing possibilities for semi-automation. We consider this novel technique as an important step forward towards routinely performed diagnostic MRD studies.


Leukemia | 1997

Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease.

Auke Beishuizen; Mac de Bruijn; M. J. Pongers-Willemse; M.-A. J. Verhoeven; E. R. Van Wering; K. Hählen; T. M. Breit; S. de Bruin-Versteeg; Herbert Hooijkaas; Jjm van Dongen

Virtually all immunoglobulin kappa (IGK) gene deletions are mediated via rearrangements of the so-called kappa deleting element (Kde). Kde rearrangements occur either to Vκ gene segments (Vκ–Kde rearrangements) or to the heptamer recombination signal sequence in the Jκ–Cκ intron. Kde rearrangements were analyzed by the polymerase chain reaction (PCR) and heteroduplex analysis in 130 B-lineage leukemias: 63 precursor-B-acute lymphoblastic leukemias (ALL) and 67 chronic B cell leukemias. To obtain detailed information about Kde rearrangements, we sequenced 109 of the 189 detected junctional regions. Vκ gene family usage in the Vκ–Kde rearrangements in our series of B-lineage leukemias was comparable to Vκ gene family usage in functional Vκ–Jκ rearrangements in normal and malignant mature B cells, except for a higher frequency of Vκ II family usage in precursor-B-ALL. Junctional region sequencing of the Kde rearrangements in precursor-B-ALL revealed a mean insertion of 4.7 nucleotides and a mean deletion of 9.5 nucleotides, resulting in an extensive junctional diversity, whereas in chronic B cell leukemias the insertion (1.9) and deletion (6.0) were significantly lower. The relatively extensive junctional diversity of the Kde rearrangements in precursor-B-ALL allowed us to design leukemia/patient-specific oligonucleotide probes, which were proven to be useful for detection of minimal residual disease (MRD) with sensitivities of 10−4 to 10−5. Kde rearrangements occur in approximately 50% of precursor-B-ALL cases and are likely to remain stable during the disease course, because Kde rearrangements are assumed to be ‘end-stage’ rearrangements, which cannot easily be replaced by continuing rearrangement processes. These findings indicate that junctional regions of Kde rearrangements in precursor-B-ALL represent new valuable patient-specific PCR targets for detection of MRD.


Leukemia | 1999

Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques.

O. J. H. M. Verhagen; A. J. M. Wijkhuijs; A J van der Sluijs-Gelling; Tomasz Szczepański; B. E. M. van der Linden-Schrever; M. J. Pongers-Willemse; E. R. Van Wering; J J M van Dongen; C. E. Van Der Schoot

Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques


Current Topics in Microbiology and Immunology | 1999

Unusual Immunoglobulin and T-cell Receptor Gene Rearrangement Patterns in Acute Lymphoblastic Leukemias

Tomasz Szczepański; M. J. Pongers-Willemse; A W Langerak; J J M van Dongen

Immunoglobulin (Ig) and T-cell receptor (TCR) genes are rearranged in virtually all acute lymphoblastic leukemia (ALL) cases. However, the recombination patterns display several unusual features as compared to normal lymphoid counterparts. Cross-lineage gene rearrangements occur in more than 90% of precursor-B-ALL and in approximately 20% of T-ALL, whereas they are rare in normal lymphocytes. Approximately 25-30% of the Ig and TCR gene rearrangements at diagnosis are oligoclonal, and can undergo continuing or secondary recombination events during the disease course. Based on our extensive molecular studies we hypothesize that the unusual Ig and TCR gene rearrangements in ALL occur as an early postoncogenic event resulting from the continuing V(D)J recombinase activity on accessible gene loci. This hypothesis is on the one hand supported by the virtual absence of cross-lineage gene rearrangements in normal lymphocytes and mature lymphoid malignancies and on the other hand by the presence of oligoclonality and secondary Ig and TCR gene rearrangements in ALL.


Leukemia | 1999

Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease

T Szczepanski; A. Beishuizen; M. J. Pongers-Willemse; K. Hählen; E. R. Van Wering; A. J. M. Wijkhuijs; G. J. M. Tibbe; M. A. C. De Bruijn; J J M van Dongen


Blood | 1999

Ig Heavy Chain Gene Rearrangements in T-Cell Acute Lymphoblastic Leukemia Exhibit Predominant Dh6-19 and Dh7-27 Gene Usage, Can Result in Complete V-D-J Rearrangements, and Are Rare in T-Cell Receptor β Lineage

Tomasz Szczepański; M. J. Pongers-Willemse; Anton W. Langerak; Wietske A. Harts; Annemarie J.M. Wijkhuijs; Elisabeth R. van Wering; Jacques J.M. van Dongen


Cancer | 1998

Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.

Tomasz Szczepa ski; M. J. Pongers-Willemse; Karel Hhlen


The Lancet | 1999

PROGNOSTIC VALUE OF MINIMA RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDHOOD. AUTHORS' REPLY

T. Matsumura; M. Kami; T. Saito; H. Sakamaki; H. Hirai; J J M van Dongen; M. J. Pongers-Willemse; Andrea Biondi; E R Panzer-Grümayer; Claus R. Bartram


Cancer | 1998

INTENSIFIED THERAPY FOR INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA : RESULTS FROM THE DANA-FARBER CANCER INSTITUTE CONSORTIUM. AUTHORS' REPLY

T Szczepanski; M. J. Pongers-Willemse; K. Hählen; J. J. M. Van Dongen


Archive | 1988

Diagnose en classificatie van leukemieën en kwaadaardige lymfomen en opsporing van "minimal residual disease"

J.J.M. (Jacques) van Dongen; W. van Ewijk; A W Langerak; M. J. Pongers-Willemse

Collaboration


Dive into the M. J. Pongers-Willemse's collaboration.

Top Co-Authors

Avatar

J J M van Dongen

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

A W Langerak

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

A. J. M. Wijkhuijs

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

K. Hählen

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Tomasz Szczepański

Medical University of Silesia

View shared research outputs
Top Co-Authors

Avatar

E. R. Van Wering

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

T Szczepanski

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar

A. Beishuizen

Erasmus University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge